Ruth Plummer

Clinical Professor

Newcastle University

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Articles (9)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2021

Year:

2021

Collaborators (17)

Patricia Roxburgh

University of Glasgow

UNITED KINGDOM

View details

Matthew Krebs

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM

View details

Martin Forster

University College London

UNITED KINGDOM

View details

Niharika Mettu

Duke University

UNITED STATES

View details

Jae-Weon Kim

Professor

Seoul National University Hospital

SOUTH KOREA

View details

Louise Carter

Clinical Senior Lecturer

The University of Manchester

UNITED KINGDOM

View details

Bart Hendriks

Novartis Institutes for BioMedical Research Inc

UNITED STATES

View details

Rebecca S. Kristeleit

University of Arizona College of Medicine

UNITED STATES

View details

Hans Prenen

Antwerp University Hospital

BELGIUM

View details

Debashis Sarker

King’s College London

UNITED KINGDOM

View details

yvette drew

Associate Professor

The University of British Columbia

CANADA

View details

Seock-Ah Im

Professor

Seoul National University College of Medicine

SOUTH KOREA

View details

Steve Wedge

Newcastle University

UNITED KINGDOM

View details

ROBERT JONES

Professor

Cardiff University

UNITED KINGDOM

View details

Elena Garralda

SPAIN

View details

Chris Plummer

Honorary Senior Lecturer

Newcastle University

UNITED KINGDOM

View details

Timothy Yap

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ruth Plummer

Research Interests

Explore related searches

Articles (9)

Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study

Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer

A Phase I Dose-escalation Study of AZD3965, an Oral Monocarboxylate Transporter 1 Inhibitor, in Patients with Advanced Cancer.

A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer

Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours

Phase I Study of Lysine-Specific Demethylase 1 Inhibitor, CC-90011, in Patients with Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Collaborators (17)

Patricia Roxburgh

Matthew Krebs

Martin Forster

Niharika Mettu

Jae-Weon Kim

Louise Carter

Bart Hendriks

Rebecca S. Kristeleit

Hans Prenen

Debashis Sarker

yvette drew

Seock-Ah Im

Steve Wedge

ROBERT JONES

Elena Garralda

Chris Plummer

Timothy Yap

Make your next move.